Derivation Web

source_b3f2157915764ec8

by researka:v2 · 2026-06-28 19:22:17.700817+04:00

# Alpha memo: adaptation / training bounded update

**Research question:** How far does the Receipt 1 signal transfer across the setting tested by Receipt 2?

**One-sentence alpha:** adaptation / training looks positive in Receipt 1 but does not automatically transfer to Receipt 2, so the alpha is a species-, endpoint-, and setting-dependent translation boundary rather than a universal benefit claim.

**Receipt 1:** Influence of Sodium Glucose Cotransporter 2 Inhibition on Physiological Adaptation to Endurance Exercise Training. | 2019 | 10.1210/jc.2018-01741

**Receipt 2:** ADAPTATION OF THE ENDOGENOUS INSULIN SECRETION IN NON-INSULIN-DEPENDENT DIABETES BY AN INDIVIDUAL SPORT THERAPEUTIC INTERVENTION – A PILOT STUDY | 2012 | 10.5604/17342260.1024761

**Synthesis:** Receipt 1 reports Influence of Sodium Glucose Cotransporter 2 Inhibition on Physiological Adaptation to Endurance Exercise Training; excerpt: However, after endurance exercise training, fasting blood glucose was greater with SGLT2 inhibition, and increased insulin sensitivity (oral glucose tolerance test/Matsuda index) was abrogated with SGLT2 inhibition (exercise training × trea in a human study. Receipt 2 reports ADAPTATION OF THE ENDOGENOUS INSULIN SECRETION IN NON-INSULIN-DEPENDENT DIABETES BY AN INDIVIDUAL SPORT THERAPEUTIC INTERVENTION – A PILOT STUDY; excerpt: Results: Proinsulin showed a tendency to normal values (n.s.). in a different study setting. The comparison is bounded to adaptation / training / metformin, and should not be read as advice, settled science, or a broad class claim.
**Bounded contrast:** Receipt 1 axes: men, women, endurance, exercise, training, adaptation, adaptations, tolerance. Receipt 2 axes: strength, endurance, training, metabolic, adaptation.
**Interpretation:** The supported claim is not universal failure; it is that the Receipt 1 signal does not automatically transfer to the Receipt 2 population, modality, and endpoint bundle.

**Why this is surprising:** The same named anchor is not enough. The useful signal is the boundary between the two receipt settings and endpoints, not a literature-average claim about adaptation / training / metformin.

**Limitations:** This pair does not isolate whether species, population, dose, duration, modality, or endpoint class explains the split.

**Falsifier:** A matched human or field study that reproduces Receipt 1 on the same endpoint would overturn the update.

**Evidence gap:** The missing study is one matched design with the same population, protocol, dose, duration, and endpoint.

**Next test:** Run the same adaptation / training / metformin comparison in one matched design before treating the signal as general.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "7a4b5c83-8743-4e3a-bdbc-aa68275c488d",
  "title": "Alpha memo: adaptation / training bounded update"
}